These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. Pratt RD. J Neurol Sci; 2002 Nov 15; 203-204():57-65. PubMed ID: 12417358 [Abstract] [Full Text] [Related]
9. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, Donepezil MSAD Study Investigators' Group. Curr Med Res Opin; 2002 Nov 15; 18(6):347-54. PubMed ID: 12442882 [Abstract] [Full Text] [Related]
10. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group. Int J Geriatr Psychiatry; 2005 Jun 15; 20(6):559-69. PubMed ID: 15920715 [Abstract] [Full Text] [Related]
11. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. Passmore AP, Bayer AJ, Steinhagen-Thiessen E. J Neurol Sci; 2005 Mar 15; 229-230():141-6. PubMed ID: 15760632 [Abstract] [Full Text] [Related]
13. Donepezil: in vascular dementia. Goldsmith DR, Scott LJ. Drugs Aging; 2003 Mar 15; 20(15):1127-36. PubMed ID: 14651435 [Abstract] [Full Text] [Related]
14. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Arch Intern Med; 1998 May 11; 158(9):1021-31. PubMed ID: 9588436 [Abstract] [Full Text] [Related]
15. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Int J Geriatr Psychiatry; 2004 Jan 11; 19(1):1-8. PubMed ID: 14716693 [Abstract] [Full Text] [Related]
16. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group. JAMA; 2004 Jan 21; 291(3):317-24. PubMed ID: 14734594 [Abstract] [Full Text] [Related]
17. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT. Dement Geriatr Cogn Disord; 1999 Jan 21; 10(3):237-44. PubMed ID: 10325453 [Abstract] [Full Text] [Related]
18. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S, Donepezil 401 Study Group. Neurology; 2004 Aug 24; 63(4):651-7. PubMed ID: 15326237 [Abstract] [Full Text] [Related]
19. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group. Neurology; 2001 Aug 28; 57(4):613-20. PubMed ID: 11524468 [Abstract] [Full Text] [Related]
20. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Clin Ther; 2010 Jul 28; 32(7):1234-51. PubMed ID: 20678673 [Abstract] [Full Text] [Related] Page: [Next] [New Search]